It was reported yesterday that A2 Biotherapeutics, a biotechnology company developing innovative cell therapies for cancer patients, has announced its official launch.

The company employs a technology to identify antibody and T-cell receptor fragments that bind to targets that are technically challenging but distinguish tumour cells. The target binder platform is integrated with proprietary cell engineering, modular vector designs, and novel quantitative assays to extend the reach of cell therapies into solid tumours.

Presently, the company has four programmes in development, with the first clinical candidate expected in 2020. It is open to collaborations to rapidly advance these programmes. The firm's plans also cover innovations in manufacturing. It will introduce an autologous cell manufacturing facility in 2020 with technology scalable for commercial launch.